First-line chemotherapy for non-small-cell lung cancer: Is there a superior regimen based on histology?

被引：44
|
作者：
Einhorn, Lawrence H. [1 ]
机构：
[1] Indiana Univ, Dept Med, Div Hematol Oncol, Indianapolis, IN 46204 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 21期
关键词：
D O I：
10.1200/JCO.2008.17.2056
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3485 / 3486
页数：2
相关论文
共 50 条
  • [21] Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: A new category of patients for clinical studies?
    Parra, HJS
    Latteri, F
    Cavina, R
    De Vincenzo, F
    Zucali, PA
    Campagnoli, E
    Santoro, A
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (06) : 1078 - 1080
  • [22] Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy
    Park, Hyung Soon
    Lim, Sun Min
    Shin, Ho Jung
    Cho, Arthur
    Shin, Jae-Gook
    Lee, Min Goo
    Kim, Hye Ryun
    Kim, Joo Hang
    Cho, Byoung Chul
    PHARMACOGENETICS AND GENOMICS, 2016, 26 (03): : 116 - 125
  • [23] Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
    Crawford, Jeffrey
    Denduluri, Neelima
    Patt, Debra
    Jiao, Xiaolong
    Morrow, Phuong Khanh
    Garcia, Jacob
    Barron, Richard
    Lyman, Gary H.
    SUPPORTIVE CARE IN CANCER, 2020, 28 (02) : 925 - 932
  • [24] Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
    Khan, Iftekhar
    Morris, Stephen
    Hackshaw, Allan
    Lee, Siow-Ming
    BMJ OPEN, 2015, 5 (07):
  • [25] ROLE OF EGFR MUTATIONAL STATUS IN RESPONSE TO FIRST-LINE CLASSICAL CHEMOTHERAPY IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER
    Franco, I.
    Antunes, A.
    Campainha, S.
    Conde, S.
    Barroso, A. M.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S45 - S45
  • [26] Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer
    Cappuzzo, F
    Novello, S
    De Marinis, F
    Franciosi, V
    Maur, M
    Ceribelli, A
    Lorusso, V
    Barbieri, F
    Castaldini, L
    Crucitta, E
    Marini, L
    Bartolini, S
    Scagliotti, GV
    Crinò, L
    BRITISH JOURNAL OF CANCER, 2005, 93 (01) : 29 - 34
  • [27] Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer
    F Cappuzzo
    S Novello
    F De Marinis
    V Franciosi
    M Maur
    A Ceribelli
    V Lorusso
    F Barbieri
    L Castaldini
    E Crucitta
    L Marini
    S Bartolini
    G V Scagliotti
    L Crinò
    British Journal of Cancer, 2005, 93 : 29 - 34
  • [28] Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer
    Lorusso, V
    Carpagnano, F
    Frasci, G
    Panza, N
    Di Rienzo, G
    Cisternino, ML
    Napoli, G
    Orlando, S
    Cinieri, S
    Brunetti, C
    Palazzo, S
    De Lena, M
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) : 405 - 411
  • [29] DOCETAXEL AND GEMCITABINE AS FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER: AN EXAMPLE OF TRANSLATIONAL RESEARCH
    Zoli, Wainer
    Cecconetto, Lorenzo
    Dall'Agata, Monia
    Riva, Nada
    Tassinari, Davide
    Calpona, Sebastiano
    Rosti, Giovanni
    Piancastelli, Alessandra
    Frassineti, Giovanni Luca
    ANNALS OF ONCOLOGY, 2004, 15 : 29 - 30
  • [30] Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
    Jeffrey Crawford
    Neelima Denduluri
    Debra Patt
    Xiaolong Jiao
    Phuong Khanh Morrow
    Jacob Garcia
    Richard Barron
    Gary H. Lyman
    Supportive Care in Cancer, 2020, 28 : 925 - 932
12345